Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P05787: Variant p.Tyr54Cys

Keratin, type II cytoskeletal 8
Gene: KRT8
Feedback?
Variant information Variant position: help 54 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance
Residue change: help From Tyrosine (Y) to Cysteine (C) at position 54 (Y54C, p.Tyr54Cys). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from large size and aromatic (Y) to medium size and polar (C) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -2 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page
Variant description: help In CIRRH. Any additional useful information about the variant.


Sequence information Variant position: help 54 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 483 The length of the canonical sequence.
Location on the sequence: help SSSSFSRVGSSNFRGGLGGG Y GGASGMGGITAVTVNQSLLS The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences. 
Human                         SSSSF---SRVGSSN--FRGGLGGG---------YGGASGMG---------GITAVTVNQSLLS

Mouse                         SSSSF---SRVGSSSSSFRGSMGTGVGL----GGFGGA-GV

Rat                           SSSSF---SRVGSSSSSFRGSLGG----------FGGA-GV

Bovine                        SSSAF---SRVGSSSS-FRGGLGTG---MSMAGSYGGAPGL

Xenopus laevis                SSASFSLGSSYGGASR-FGSGYRSG---------FGGA-GV

Zebrafish                     SYSAR---SSYGGVNRGMGAGMGGGSGFISSSSAYGLGMGM
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 1 – 483 Keratin, type II cytoskeletal 8
Region 1 – 90 Head
Modified residue 34 – 34 Phosphoserine
Modified residue 37 – 37 Phosphoserine
Modified residue 39 – 39 Phosphoserine
Modified residue 40 – 40 Omega-N-methylarginine
Modified residue 43 – 43 Phosphoserine
Modified residue 44 – 44 Phosphoserine
Modified residue 47 – 47 Asymmetric dimethylarginine; alternate
Modified residue 47 – 47 Omega-N-methylarginine; alternate
Modified residue 74 – 74 Phosphoserine; by MAPK
Mutagenesis 72 – 72 L -> P. Increases phosphorylation.
Mutagenesis 74 – 74 S -> A. Generates normal-appearing filaments, that remain stable after okadaic acid treatment.
Mutagenesis 74 – 74 S -> D. Generates normal-appearing filaments, that are destabilized by okadaic acid.
Beta strand 53 – 57



Literature citations
Keratin 8 and 18 mutations are risk factors for developing liver disease of multiple etiologies.
Ku N.-O.; Darling J.M.; Krams S.M.; Esquivel C.O.; Keeffe E.B.; Sibley R.K.; Lee Y.M.; Wright T.L.; Omary M.B.;
Proc. Natl. Acad. Sci. U.S.A. 100:6063-6068(2003)
Cited for: VARIANTS CIRRH VAL-53; CYS-54 AND CYS-62; VARIANT VAL-63;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.